Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease
Description
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). MeSH
Hierarchy View
Subtype Terms (26)
Candidiasis, Chronic Mucocutaneous
1 approved drug
Chemical and Drug Induced Liver Injury, Chronic
1 approved drug
Chronic Exertional Compartment Syndrome
3 approved drugs
Chronic Kidney Disease-Mineral and Bone Disorder
126 drugs (80 approved, 46 experimental)
Chronic Limb-Threatening Ischemia
70 drugs (26 approved, 44 experimental)
Chronic Periodontitis
87 drugs (38 approved, 49 experimental)
Chronic Urticaria
47 drugs (23 approved, 24 experimental)
Granulomatous Disease, Chronic
45 drugs (28 approved, 17 experimental)
Hematoma, Subdural, Chronic
18 drugs (17 approved, 1 experimental)
Hepatitis, Chronic
21 drugs (13 approved, 8 experimental)
Leukemia, Lymphocytic, Chronic, B-Cell
602 drugs (221 approved, 381 experimental)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
246 drugs (129 approved, 117 experimental)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
129 drugs (101 approved, 28 experimental)
Leukemia, Myelomonocytic, Chronic
216 drugs (116 approved, 100 experimental)
Leukemia, Neutrophilic, Chronic
35 drugs (30 approved, 5 experimental)
Multiple Chronic Conditions
2 drugs (1 approved, 1 experimental)
Multiple Sclerosis, Chronic Progressive
70 drugs (39 approved, 31 experimental)
Ophthalmoplegia, Chronic Progressive External
1 approved drug
Pancreatitis, Chronic
42 drugs (27 approved, 15 experimental)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
30 drugs (20 approved, 10 experimental)
Pulmonary Disease, Chronic Obstructive
457 drugs (211 approved, 246 experimental)
Renal Insufficiency, Chronic
432 drugs (242 approved, 190 experimental)
Wasting Disease, Chronic
14 drugs (3 approved, 11 experimental)
Phase 1 Indicated Drugs (4)
Other Experimental Indicated Drugs (19)
Organization Involved with Phase 4 Indications (31)
Organization Involved with Phase 3 Indications (35)
Organization Involved with Phase 2 Indications (34)
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (16)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.